BCL2L1 and cancer: Thus, the expected rule of a higher level of overall priming underlying the acquisition of sensitivity of TIS cancer cells to (BCL-xL-targeting) BH3 senolytics appears to hold when comparing TIS phenotypes among themselves, but does not hold when considering the mitochondrial priming status of proliferative controls.